Capstone Therapeutics to Present at 9th Annual BIO Investor Forum
02 Octobre 2010 - 1:45AM
Capstone Therapeutics (Nasdaq:CAPS) is scheduled
to make a presentation at the 9th Annual BIO Investor Forum, Palace
Hotel, 2 New Montgomery Street, San Francisco, CA on Tuesday,
October 5, 2010 at 3:00pm EDT. Dana B. Shinbaum, Vice President,
Business Development will provide an overview and discuss the
Company's current operating environment and business strategy.
The presentation slides may be accessed through the Company's
website at www.capstonethx.com under "Investors".
About Capstone Therapeutics
Capstone Therapeutics is a biotechnology company committed to
developing a pipeline of novel therapeutic peptides aimed at
helping patients with under-served medical conditions. The
Company is focused on development and commercialization of two
product platforms: AZX100 and Chrysalin (rusalatide acetate or
TP508).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new
class of compounds in the field of smooth muscle relaxation and
fibrosis. Based on its demonstrated effects in pre-clinical
models and safety in clinical trials, AZX100 is currently being
evaluated for commercially significant medical applications such as
the prevention or reduction of hypertrophic and keloid scarring and
treatment of pulmonary fibrosis. Capstone has an exclusive
worldwide license to AZX100.
Chrysalin, the Company's novel synthetic 23-amino acid peptide,
has been proven in multiple pre-clinical and clinical models to
stimulate cellular events leading to angiogenesis,
revascularization, and repair of dermal and musculoskeletal
tissues. It is currently being evaluated in disorders that
involve vascular endothelial dysfunction, such as acute myocardial
infarction and chronic myocardial ischemia. The Company owns
exclusive worldwide rights to Chrysalin.
Capstone's corporate headquarters are in Tempe,
Arizona. For more information, please visit the Company's
website: www.capstonethx.com.
The Capstone Therapeutics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5429
Statements in this press release or otherwise attributable to
Capstone regarding our business that are not historical facts are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements, which include the timing and acceptability of FDA
filings and the efficacy and marketability of potential products,
involve risks and uncertainties that could cause actual results to
differ materially from predicted results. These risks include:
delays in obtaining or inability to obtain FDA, institutional
review board or other regulatory approvals of pre-clinical or
clinical testing; unfavorable outcomes in our pre-clinical and
clinical testing; the development by others of competing
technologies and therapeutics that may have greater efficacy or
lower cost; delays in obtaining or inability to obtain FDA or other
necessary regulatory approval of our products; our inability to
successfully and cost effectively develop or outsource
manufacturing and marketing of any products we are able to bring to
market; changes in FDA or other regulations that affect our ability
to obtain regulatory approval of our products, increase our
manufacturing costs or limit our ability to market our product;
effects of the Capstone Stockholder Put Right on our stock price,
liquidity or our ability to continue operations; effects on our
stock price and liquidity if we are unable to meet the requirements
for continued listing on the Nasdaq Capital Market; our need for
additional capital in the future to fund the continued development
of our product candidates; and other factors discussed in our Form
10-K for the fiscal year ended December 31, 2009, and other
documents we file with the Securities and Exchange Commission.
Editor's Note: This press release is also available under
the Investors section of the Company's website at
www.capstonethx.com.
CONTACT: Capstone Therapeutics
Karen Struck, Investor Relations
(602) 286-5250
kstruck@capstonethx.com
The Trout Group
Lauren Glaser
(415) 392-3310
lglaser@troutgroup.com
Capstone Therapeutics Corp (MM) (NASDAQ:CAPS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Capstone Therapeutics Corp (MM) (NASDAQ:CAPS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024